Vulvar cancer market grows with new immunotherapies but faces cost and access challenges.

The global vulvar cancer market is expanding due to rising cases linked to aging populations and HPV infections. Advances in immunotherapies, targeted treatments, and minimally invasive surgeries are improving patient outcomes and driving market growth. However, high treatment costs and limited access, especially in lower-income regions, remain significant barriers. Innovations in early detection, personalized medicine, and global health initiatives are expected to further boost the market and improve care quality worldwide.